Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

COPENHAGEN, Denmark, March 5, 2025– Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the Company's shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such, which are hereby reported in accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523.The transactions relate to the award and vesting of restricted stock units...

Hellerup, 05/03/2025 (informazione.news - comunicati stampa - salute e benessere)

– Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the Company's shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such, which are hereby reported in accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523.

The transactions relate to the award and vesting of restricted stock units (RSUs) under the short-term incentive scheme for the Company's Executive Management. The scheme is cash-based; however, in accordance with the Company's remuneration policy, the Board of Directors may decide to defer the bonus, in full or in part, by conversion of the cash bonus into RSUs including matching shares, which have a vesting period of a minimum of three years after grant. The reported award transactions relate to the Executive Management's performance in 2024, for which 50% of the cash bonus has been converted into RSUs, in addition to matching shares. The reported vesting transactions related to RSUs and matching shares awarded in 2022, using the principle as outlined above.

Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com.

Europe: Rolf Sass Sørensen, Vice President Investor Relations, rss@bavarian-nordic.com, Tel: +45 61 77 47 43
US: Graham Morrell, Paddock Circle Advisors, graham@paddockcircle.com, Tel: +1 781 686 9600

Nicole Seroff, Vice President Corporate Communications, nise@bavarian-nordic.com, Tel: + 45 53 88 06 03

Company Announcement no. 10 / 2025

Attachment